Efepoetin Alfa not checked
Genexine, Inc. · GX-E4
FollowEvery change as it happens, and a Monday email
Trials
1 active
3 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Efepoetin alfa (Epoetin-Fc fusion protein, GX-E2 or GX-E4,) is a novel long-acting erythropoietin-hybrid fragment crystallizable (Fc) fusion protein developed by Genexine, intended for treatment and maintenance of anemia due to CKD with or without dialysis. Its drug substance is a recombinant form of human EPO and hybrid Fc (hyFc®) fragment consisting of 2 subunits with a total of 411 amino acid…”In the company’s words, NCT06466785 on ClinicalTrials.gov
- Tested for
- Anemia of Chronic Kidney Disease
- Main trialPhase 3
- “An investigator-blinded, randomized, multicenter, active-controlled Phase III study for the treatment of anemia in patients with CKD on hemodialysis”In the company’s words, NCT06466785 on ClinicalTrials.gov
- Other names
- GX-E4
- Given with
- Mircera (Hoffman-LA Roche)Other companies’ drugs in its trials
Other drugs for Anemia of Chronic Kidney Disease
- MT1013Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Phase 3
- BaxdrostatAstraZeneca · Phase 3
- EmpagliflozinBoehringer Ingelheim · Phase 3
- Migalastat HClAmicus Therapeutics · Phase 3
- VicadrostatBoehringer Ingelheim · Phase 3
- XyloCore StrenghtIperboreal Pharma Srl · Phase 3
Coming up1
- Jun 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Jun 2027 | A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis | |
| Phase 3Completed | 30 Mar 2022 | A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient | |
| Phase 1Completed | 25 Mar 2025 | Clinical Trial of Efepoetin Alfa in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026